Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, FluoroPharma Medical's Enterprise Value is $0.01 Mil.
FluoroPharma Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2016 was $-0.88 Mil. Therefore, FluoroPharma Medical's EV-to-OCF for today is -0.01.
The historical rank and industry rank for FluoroPharma Medical's EV-to-OCF or its related term are showing as below:
FPMI'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.01 Med: 0 Max: -0.01
Current: -0.01
During the past 10 years, the highest EV-to-OCF of FluoroPharma Medical was -0.01. The lowest was -0.01. And the median was .
FPMI's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.23
vs FPMI: -0.01
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
FluoroPharma Medical (OTCPK:FPMI) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
FluoroPharma Medical's PE Ratio (TTM) for today is calculated as:
FluoroPharma Medical's share price for today is $0.0002.
FluoroPharma Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.087.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
FluoroPharma Medical EV-to-OCF Related Terms
FluoroPharma Medical EV-to-OCF Historical Data
* Premium members only.
The historical data trend for FluoroPharma Medical's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, FluoroPharma Medical's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
FluoroPharma Medical EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where FluoroPharma Medical's EV-to-OCF falls into.
FluoroPharma Medical's current Enterprise Value is $0.01 Mil.
FluoroPharma Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FluoroPharma Medical (FPMI) has a EV-to-OCF of -0.01 as of Aug. 02, 2026.
Is FluoroPharma Medical's EV-to-OCF too high?
FluoroPharma Medical's current EV-to-OCF is -0.01.
How does FluoroPharma Medical's EV-to-OCF compare to HSTC and OBMPD?
FluoroPharma Medical's EV-to-OCF of -0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. FluoroPharma Medical's current EV-to-OCF is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FluoroPharma Medical stock overvalued right now?
FluoroPharma Medical (FPMI) has a current EV-to-OCF of -0.01. The current EV-to-OCF is -0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For FluoroPharma Medical (FPMI), the current EV-to-OCF is -0.01 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FPMI has been successfully added to your 
